Aarti Drugs published its audited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1FY27) in two newspapers on August 2, 2026. The results were published in Financial Express (English) and Pratahkal (Marathi), as required under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This publication ensures wider accessibility of the company’s financial performance to investors and stakeholders across different language preferences.

Publication Details

The financial results were formally submitted to the Listing/Compliance Departments of both BSE Limited and the National Stock Exchange of India Limited on August 3, 2026. The submission was signed by Rushikesh Vivek Deole, Company Secretary & Compliance Officer of Aarti Drugs Limited. The publication serves as a regulatory compliance measure, ensuring that all shareholders have equal access to the company’s financial information.

Financial Results Overview

The published results confirm the previously reported financial performance for Q1FY27. Consolidated revenue stood at ₹703.59 crore, while consolidated profit after tax (PAT) was ₹50.13 crore. Standalone revenue was ₹627.65 crore with a PAT of ₹50.85 crore. These figures align with the earlier disclosures made by the company regarding its strong operational performance in the quarter.

Regulatory Compliance

The results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 31, 2026. The statutory auditors carried out an audit of the financial results and expressed an unmodified audit opinion. The company has three subsidiaries — Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SpA — along with two step-down subsidiaries, Pharma Go SpA and Tripharma Chile SpA.

What the Numbers Show

The dual-language publication strategy reflects Aarti Drugs’ commitment to inclusive investor communication. By publishing in both English and Marathi, the company ensures that regional investors who may prefer local language media can access critical financial information without barriers. This approach enhances transparency and broadens the reach of the company’s financial disclosures beyond traditional English-speaking investor circles.

Aarti Drugs has approved a comprehensive leadership transition effective October 1, 2026, elevating Rashesh C. Gogri to Chairman and appointing Adhish P. Patil as Managing Director. The Board of Directors also accepted the early retirement of Prakash M. Patil, who has served as Chairman and Managing Director since 2014, citing the need for an orderly succession plan. This restructuring aims to maintain strategic continuity while injecting fresh leadership into key executive roles ahead of Prakash M. Patil’s term expiry in May 2027.

Key Leadership Changes

The Board meeting held on July 31, 2026, finalized several critical appointments and re-appointments subject to shareholder approval at the ensuing Annual General Meeting (AGM). The changes reflect a blend of internal promotions and continuity in governance.

Rashesh C. Gogri, who has been Managing Director since September 2014, brings over 27 years of experience in production, marketing, and project implementation. He also serves as Vice-Chairman & Managing Director of Aarti Industries Limited. Adhish P. Patil, currently Chief Financial Officer since April 2014, holds an MBA in Finance and Marketing from the University of Florida’s Warrington College of Business Administration. His appointment is contingent upon shareholder approval.

Additional Board Appointments

The Board also approved the following appointments and re-appointments, all subject to shareholder approval:

• Nilesh B. Patil: Appointed as Whole-time Director for a five-year term starting from the conclusion of the AGM, replacing Uday M. Patil who retires by rotation and has not offered himself for re-appointment. Nilesh B. Patil has been with the company for over 33 years.
• Harshit M. Savla: Re-appointed as Joint Managing Director for five years effective June 1, 2027.
• Harit P. Shah: Re-appointed as Whole-time Director for five years effective June 1, 2027.
• Independent Directors: Hasmukh B. Dedhia, Ajit E. Venugopalan, and Sandeep M. Joshi are re-appointed for second terms of five years each, effective March 29, 2027.

Prakash M. Patil will continue to provide guidance and strategic support to ensure a smooth transition despite his early departure from executive roles. The Board expressed deep appreciation for his visionary leadership since the company’s inception in 1984.

Committee Reconstitution

Consequent to these changes, the Board reconstituted its committees effective October 1, 2026:

• Audit Committee: Chaired by Hasmukh B. Dedhia, with members including Ankit V. Paleja, Neha R. Gada, Ajit E. Venugopalan, Rashesh C. Gogri, and Adhish P. Patil.
• Nomination and Remuneration Committee: Chaired by Neha R. Gada, with members Bhaskar N. Thorat, Ankit V. Paleja, and Rashesh C. Gogri.
• Risk Management Committee: Chaired by Rashesh C. Gogri, with a broad membership including Adhish P. Patil, Harshit M. Savla, Harit P. Shah, Narendra J. Salvi, Nilesh B. Patil, Ankit V. Paleja, Bhaskar N. Thorat, and Dhanaji L. Kakade.
• Corporate Social Responsibility Committee: Chaired by Bhaskar N. Thorat, with Adhish P. Patil and Rashesh C. Gogri as members.
• Finance and Investment Committee: Chaired by Rashesh C. Gogri, with Adhish P. Patil, Harshit M. Savla, Harit P. Shah, and Nilesh B. Patil as members.

What the Numbers Show

The retention of senior leadership within the organization signals stability for investors. By promoting executives who have grown within the company, Aarti Drugs mitigates the risks often associated with external hires. The transition maintains the company’s long-term strategic direction, focusing on scaling operations in Active Pharmaceutical Ingredients (APIs) and specialty chemicals through its 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh. The early retirement of Prakash M. Patil, whose term was set to expire in May 2027, underscores a proactive approach to governance and succession planning.